Cantor Fitzgerald Remains a Buy on LifeMD (LFMD)
Cantor Fitzgerald's Sarah James maintains a Buy rating on LifeMD with a $15.00 price target. LifeMD shares closed at $4.73, indicating significant upside potential. James, a 4-star analyst, has a 5.0% average return and a 55.52% success rate. The Street consensus suggests a Strong Buy with a $13.00 average price target, a 174.84% upside. Lake Street also maintains a Buy rating with a $14.00 target.
In a report released yesterday, Sarah James from Cantor Fitzgerald maintained a Buy rating on LifeMD, with a price target of $15.00. The company’s shares closed yesterday at $4.73.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, James is a 4-star analyst with an average return of 5.0% and a 55.52% success rate. James covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Centene, and HCA Healthcare.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for LifeMD with a $13.00 average price target, representing a 174.84% upside. In a report released yesterday, Lake Street also maintained a Buy rating on the stock with a $14.00 price target.
